|

Polyphenol Metabotypes in People With Diabetes Type 2

RECRUITINGSponsored by University Hospital, Ghent
Actively Recruiting
SponsorUniversity Hospital, Ghent
Started2026-03-04
Est. completion2028-11
Eligibility
Age40 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06810635

Summary

This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).

Eligibility

Age: 40 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* all participants
* between 40-85 years
* age-matched individuals without diabetes
* BMI between 18.5-30
* no metabolic syndrome
* persons with T2DM
* at leats 2 years of clinical diagnoses of T2DM
* stable medication use for at least 1 month

Exclusion Criteria:

* pregnancy of breastfeeding
* in last month
* acute use of anti/pre/probiotics
* start of new drug or dietary supplements
* major changes in diet
* major lifestyle changes
* diseases
* Gastrointestinal diseases (inflammatory bowel disease)
* Bariatric surgery
* Other forms of diabetes (cystic fibrosis/MODY/T1DM)
* Heart problems (NYHA 3/4) or previous cardiovascular events
* Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis
* Lung problems (COPD - GOLD 3/4), cystic fibrosis
* Uncontrolled thyroid function disruption in the past 6 months
* Intake of coumarin derivatives and direct oral anticoagulant medication
* Anti-cancer treatment: chemo-/immunotherapy
* Immonosuppressants (transplant)
* Antiepileptic drugs

Conditions2

DiabetesType 2 Diabetes Mellitus (T2DM)

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.